Last-Hope drug access opens for rare immune diseases
NCT ID NCT07244289
Summary
This is a special access program, not a traditional clinical trial. It provides the experimental drug ianalumab (VAY736) to patients with serious immune conditions like Primary Immune Thrombocytopenia (ITP) and Sjögren's Syndrome. The program is for patients who have no other treatment options available and cannot join regular clinical trials. Doctors can request access for individual patients who meet strict medical criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJÖGREN´S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.